Top Research Reports for McDonald's, Abbott & O'Reilly Automotive

28.03.25 19:07 Uhr

Werte in diesem Artikel
Aktien

119,00 EUR -0,84 EUR -0,70%

Indizes

PKT PKT

16.550,6 PKT -1.050,4 PKT -5,97%

16.315,7 PKT -573,6 PKT -3,40%

2.600,7 PKT -135,8 PKT -4,96%

5.396,5 PKT -274,5 PKT -4,84%

Friday, March 28, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including McDonald's Corp. (MCD), Abbott Laboratories (ABT) and O'Reilly Automotive, Inc. (ORLY), as well as a micro-cap stock MIND Technology, Inc. (MIND). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>>Ahead of Wall StreetThe daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.You can read today's AWS here >>> PCE Levels Steady-to-Warmer; Pre-Markets DownToday's Featured Research ReportsMcDonald's shares have outperformed the Zacks Retail - Restaurants industry year-to-date (+7.2% vs. +3.8%). The company is benefiting from its in-house initiatives like the Accelerating the Arches strategy, menu innovation, value offerings and global expansion strategies. It plans to open approximately 2,200 restaurants globally in 2025, with opening 50,000 restaurants by 2027. Earnings estimates for 2025 have moved north in the past seven days, depicting analysts’ optimism about the stock’s growth potential. However, the decline in average checks in the United States and negative comparable sales in the United Kingdom and China are concerning. Also, inflationary pressures are still weighing down consumer spending. It expects to witness labor, food, paper and commodity inflation in 2025.(You can read the full research report on McDonald's here >>>)Shares of Abbott have outperformed the Zacks Medical - Products industry over the past year (+18.0% vs. +9.0%). The company’s pipeline is unlocking new growth opportunities, supporting the company’s positive momentum and strong growth outlook for 2025. Freestyle Libre, Lingo and Libre Rio CGM devices are on a great trajectory. Alinity, the company’s next-generation suite of systems, is a key driver in the core lab diagnostics business. Abbott is optimistic about its latest progress with biosimilars and expects this to significantly boost EPD sales, beginning 2025. Within Nutrition, despite softness in its international pediatric arm, Abbott is regaining market share banking on strong Adult Nutrition business. Yet, the significant runoff of COVID-19 testing-related sales is hurting Abbott’s Diagnostics growth. Headwinds such as tough macro conditions and foreign exchange also adds to the worry. (You can read the full research report on Abbott here >>>)O'Reilly Automotive’s shares have outperformed the Zacks Automotive - Retail and Wholesale - Parts industry over the past year (+24.4% vs. +10.3%). The company has been generating record revenues for 32 consecutive years and the trend is likely to continue on the back of growth in the auto parts market, vehicle longevity, store expansion, a strong distribution network and a customer-centric business model. O'Reilly Automotive plans to increase its inventory level for the rest of the year to keep products available in all the markets it serves. However, the company has slashed guidance for comps growth and operating margins due to the unpredictability associated with the fourth quarter. It also expects challenges in its DIY business as sales with higher margins have slowed more than expected. The company’s high capex needs to develop advanced superior offerings might limit its cash flows. Thus, the stock warrants a cautious stance.(You can read the full research report on O'Reilly Automotive here >>>)Shares of MIND Technology have outperformed the Zacks Technology Services industry over the past year (+27.5% vs. +9.9%). This microcap company with market capitalization of $8.63 million is benefiting from strong revenue growth, reaching $31.8 million for the nine months ended Oct. 31, 2024, driven by a robust $26.2 million backlog and a sales pipeline exceeding twice that amount. Net income of $3 million marks a turnaround from a $1.2 million prior-year loss, reflecting cost efficiencies and restructuring. Recurring after market services, which comprise 40% of revenues, provide stable, high-margin income. Gross margins improved to 45%, supported by pricing power, higher-margin product sales and operational efficiencies. A debt-free balance sheet with $3.5 million in cash enhances financial flexibility. However, elevated inventory levels pose liquidity risks, and reliance on energy exploration exposes MIND to sector cyclicality. Competition from larger players, geopolitical risks, R&D uncertainties, and slow software adoption present additional challenges.(You can read the full research report on MIND Technology here >>>)Other noteworthy reports we are featuring today include Equinor ASA (EQNR), DuPont de Nemours, Inc. (DD) and Mettler-Toledo International Inc. (MTD).Mark VickerySenior EditorNote: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>Today's Must ReadAccretive Business Plans Aid McDonald's (MCD), High Costs AilMarket Expansion, EPD Business Growth Aid Abbott (ABT)International Expansion to Aid O'Reilly Amid Rising ExpensesFeatured ReportsEquinor's (EQNR) Strong Project Lineup Fuels Future GrowthPer the Zacks analyst, Equinor's strong project pipeline, including Johan Sverdrup and Northern Lights CCS, drives long-term growth. However, rising costs and high debt could strain profitability.Productivity Actions, New Products Aid DuPont (DD)While DuPont faces headwinds from weaker pricing and hefty business separation costs, it should gain from productivity improvement actions and new product launches, per the Zacks analyst.Mettler-Toledo (MTD) Rides on Solid Process Analytics DemandPer the Zacks analyst, strong demand for process analytics and analytical instruments is benefiting Mettler-Toledo's prospects.Loan Growth Supports Huntington (HBAN) Amid Rising CostsPer the Zacks analyst, Huntington's accelerated loan growth, along with a rise in deposit balance, supports its financials. Yet, rising costs are concerning.Air Lease (AL) Benefits From Fleet Growth Amid Rising CostsThe Zacks Analyst is impressed with the fact that constant fleet growth is aiding Air Lease's (AL) top line. However, rising operating expenses might weigh on its bottom line.New UpgradesSolid Collectibles Business to Lift GameStop's (GME) SalesPer the Zacks analyst, GameStop's collectibles business demonstrated impressive growth in the fiscal fourth quarter, with sales increasing 15.8% year over year to $270.6 million from $233.7 million. Solid Growth Momentum, New Launches Aid CommScope (COMM)Per the Zacks analyst, solid growth momentum and product innovation are boosting CommScope's top line. Portfolio enhancements further aid the company.New DowngradesFalling Module Prices Continue to Hit Canadian Solar (CSIQ)Per the Zacks analyst, falling module selling price may continue to hurt Canadian Solar's revenue in the near term. Yet, it boasts solid project pipeline that may boost growth in long run.Expenses, Volatile Trading Revenues to Hurt Jefferies (JEF)Per the Zacks analyst, rising operating expenses, volatile trading revenues given reliance on capital markets, and regulatory risks in light of global presence, will likely hurt Jefferies' financials.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report McDonald's Corporation (MCD): Free Stock Analysis Report DuPont de Nemours, Inc. (DD): Free Stock Analysis Report O'Reilly Automotive, Inc. (ORLY): Free Stock Analysis Report Mettler-Toledo International, Inc. (MTD): Free Stock Analysis Report MIND Technology, Inc. (MIND): Free Stock Analysis Report Equinor ASA (EQNR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Abbott Laboratories und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Abbott Laboratories

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Abbott Laboratories

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Abbott Laboratories

Wer­bung

Analysen zu Abbott Laboratories

DatumRatingAnalyst
27.08.2020Abbott Laboratories SellGoldman Sachs Group Inc.
16.10.2018Abbott Laboratories OverweightBarclays Capital
25.01.2018Abbott Laboratories BuyStifel, Nicolaus & Co., Inc.
15.12.2017Abbott Laboratories OutperformBMO Capital Markets
19.10.2017Abbott Laboratories BuyStifel, Nicolaus & Co., Inc.
DatumRatingAnalyst
16.10.2018Abbott Laboratories OverweightBarclays Capital
25.01.2018Abbott Laboratories BuyStifel, Nicolaus & Co., Inc.
15.12.2017Abbott Laboratories OutperformBMO Capital Markets
19.10.2017Abbott Laboratories BuyStifel, Nicolaus & Co., Inc.
19.10.2017Abbott Laboratories OutperformRBC Capital Markets
DatumRatingAnalyst
23.07.2015Abbott Laboratories Equal WeightBarclays Capital
27.03.2015Abbott Laboratories Equal WeightBarclays Capital
30.01.2015Abbott Laboratories Equal WeightBarclays Capital
07.01.2013Abbott Laboratories haltenDeutsche Bank Securities
29.11.2012Abbott Laboratories neutralSarasin Research
DatumRatingAnalyst
27.08.2020Abbott Laboratories SellGoldman Sachs Group Inc.
25.10.2011Abbott Laboratories sellCitigroup Corp.
05.10.2011Abbott Laboratories sellCitigroup Corp.
22.11.2006Advanced Medical Optics sellCitigroup
11.09.2006Abbott Laboratories reduceUBS

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Abbott Laboratories nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen